홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

날트렉손메틸브로마이드

Methylnaltrexone Bromide

HCID 5361917
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
73232-52-7
표준 SMILES
C[N+]1(CC2CC2)CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.[Br-]
InChIKey
IFGIYSGOEZJNBE-KNLJMPJLSA-N
분자식
C21H26BrNO4
평균 분자량
436.3 g/mol
단동위원소 질량
435.10452041

개요

Methylnaltrexone Bromide is the bromide salt form of methylnaltrexone, a methyl derivative of noroxymorphone with selective, peripherally-acting mu-opioid receptor antagonistic activity. Methylnaltrexone displaces opioids from peripheral opioid receptors in the gastrointestinal tract, the bladder, and the skin, thereby reversing the opioid-related peripheral side-effects, such as constipation, urinary retention, and pruritis, respectively. Unlike naltrexone and due to the presence of a positively charged nitrogen atom in methylnaltrexone, this agent does not cross the blood-brain barrier and does not affect the centrally-mediated analgesic effect of opioids.

이름 및 식별자

우선 이름
Methylnaltrexone Bromide
IUPAC
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium-7-one bromide
현지명
날트렉손메틸브로마이드
영어명
Naltrexone methylbromide
분자식
C21H26BrNO4
분자량
436.35

이름 및 동의어

Methylnaltrexone bromideRelistorN-Methylnaltrexone BromideNaltrexone methobromideMRZ-2663BRMOA-728bromuro de metilnaltrexonabromure de methylnaltrexoneMRZ2663BRMOA728DTXSID30868236NALTREXONE METHYLBROMIDE
이름 더 보기
날트렉손메틸브로마이드MNTXUnii-rfo6il3D3mAdamantane Impurity 52Methylnatrexone bromideMethyhaaltrexone broMide
methylnaltrexoni bromidumRefChem:56830A06AH01DTXCID40820845morphinan-17-ium-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-, bromide, (5alpha,17R)-916055-92-0RFO6IL3D3M73232-52-7

데이터베이스 식별자

CAS
73232-52-7
PubChem CID
5361917
DTXSID
DTXSID30868236
ChEMBL
CHEMBL1201770
EC Number
615-932-9

물성

구조 계산 물성

극성 표면적
66.8 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
5
회전 가능 결합 수
2
무거운 원자 수
27
형식 전하
0
복잡도
664

실험 및 물리화학적 성질

Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Narcotic Antagonists

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
237 · 237-239°C
저장 조건
-20 °C · -20°C
용해도
2 O: · H2O: ≥5mg/mL
물리적 상태
가루
색상
흰색에서 베이지색
수용성
2 O: · H2O: ≥5mg/mL
안정성
흡습성
InChIKey
IFGIYSGOEZJNBE-NIWJRJBUNA-N
SMILES
O[C@]12CCC(=O)[C@]3([H])OC4=C(C=CC5C[C@@]1([H])[N+](C)(CC1CC1)CC[C@@]23C4=5)O.[Br-] |&1:1,6,15,25,r|

화학적 성질

Pale Pink Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H301 (66.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P233, P260, P261, P264, P270, P271, P272, P273, P280, P284, P301+P316, P301+P317, P302+P352, P304+P340, P317, P321, P330, P333+P317, P342+P316, P362+P364, P391, P403, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 57 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 3 (66.7%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Methylnaltrexone bromide

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
3
rtecs
QD0188550
ridadr
UN 2811 6.1 / PGIII
HS 번호
2934990002
risk_code
25-50
hazard_code
T,N
safety_code
45-61
Hazard Classifications
STOT SE 2 Oral
스토리지 클래스

화학 및 산업

약리 정보

ATC Code · 3건

A06AH01

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

FDA Pharmacological Classification · 2건

METHYLNALTREXONE BROMIDE

Opioid Antagonists [MoA]; Quaternary Ammonium Compounds [CS]; Opioid Antagonist [EPC]

MeSH Pharmacological ClassificationAgents inhibiting the effect of narcotics on the central nervous system.
응용 분야 · 3건

개요The widespread efficacy of opioids in treating patients with moderate to severe acute and chronic pain is often accompanied by untoward side effects. In particular, opioid-induced bowel dysfunction is one of the more common and debilitating consequences afflicting up to 50% of patients. To counteract the peripherally-mediated adverse effects, opioid antagonists such as naloxone, naltrexone, and nalmephene are sometimes prescribed. The latest market entry exploits a strategic modification of naltrexone to lower its lipid solubility and increase its polarity: quaternization of the amine of naltrexone by methylation (methyl bromide) prevents crossing of the blood–brain barrier thereby creating an effective peripheral antagonist. Despite a loss of potency upon methylation, methylnaltrexone antagonizes opioid binding at m-opioid receptors with an IC50 of 70 nM. Its affinity for k-opioid receptors is approximately eightfold less (IC50= 575 nM) with no significant binding to d-opioid, orphanin, or non-opioid receptors. Methylnaltrexone bromide has been approved for the treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.Regarding metabolism, methylnaltrexone bromide is eliminated primarily as intact drug (85% based on administered radioactivity) by slightly more renal than hepatic clearance.The most common adverse events were abdominal pain and flatulence followed by nausea, dizziness, and diarrhea.

용도A metabolite of Naltrexone (N285750). Methylnaltrexone (MNTX), a selective μ-opioid receptor antagonist, functions as a peripherally acting receptor antagonist in tissues of the gastrointestinal tract.

관련 반응

5건
반응 기록 만들기
HRID 47066 반응식
HRID 47066생성물로
HRID 533704 반응식
HRID 533704생성물로
HRID 1482461 반응식
HRID 1482461반응물로
HRID 1798791 반응식
HRID 1798791생성물로
HRID 2243414 반응식
HRID 2243414생성물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
11 - Combustible Solids

일반 설명Methylnaltrexone does not cross blood brain barrier and does not affect the opioid effects in the brain, such as analgesia. It is used to treat opioid-induced constipation (OIC).